|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PRICKLE1 |
Gene summary for PRICKLE1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PRICKLE1 | Gene ID | 144165 |
| Gene name | prickle planar cell polarity protein 1 | |
| Gene Alias | EPM1B | |
| Cytomap | 12q12 | |
| Gene Type | protein-coding | GO ID | GO:0001568 | UniProtAcc | A0A024R0W7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 144165 | PRICKLE1 | LZE4T | Human | Esophagus | ESCC | 4.04e-09 | 3.64e-01 | 0.0811 |
| 144165 | PRICKLE1 | P2T-E | Human | Esophagus | ESCC | 6.10e-04 | 1.23e-01 | 0.1177 |
| 144165 | PRICKLE1 | P5T-E | Human | Esophagus | ESCC | 3.64e-09 | 2.72e-01 | 0.1327 |
| 144165 | PRICKLE1 | P8T-E | Human | Esophagus | ESCC | 1.37e-02 | 1.07e-01 | 0.0889 |
| 144165 | PRICKLE1 | P9T-E | Human | Esophagus | ESCC | 1.42e-03 | 1.27e-01 | 0.1131 |
| 144165 | PRICKLE1 | P10T-E | Human | Esophagus | ESCC | 1.35e-47 | 8.17e-01 | 0.116 |
| 144165 | PRICKLE1 | P11T-E | Human | Esophagus | ESCC | 4.82e-04 | 3.21e-01 | 0.1426 |
| 144165 | PRICKLE1 | P12T-E | Human | Esophagus | ESCC | 2.13e-14 | 5.12e-01 | 0.1122 |
| 144165 | PRICKLE1 | P15T-E | Human | Esophagus | ESCC | 6.13e-03 | 1.83e-01 | 0.1149 |
| 144165 | PRICKLE1 | P16T-E | Human | Esophagus | ESCC | 2.20e-03 | 9.53e-02 | 0.1153 |
| 144165 | PRICKLE1 | P20T-E | Human | Esophagus | ESCC | 1.95e-14 | 4.01e-01 | 0.1124 |
| 144165 | PRICKLE1 | P21T-E | Human | Esophagus | ESCC | 5.80e-05 | 2.25e-02 | 0.1617 |
| 144165 | PRICKLE1 | P22T-E | Human | Esophagus | ESCC | 2.29e-12 | 3.23e-01 | 0.1236 |
| 144165 | PRICKLE1 | P23T-E | Human | Esophagus | ESCC | 1.98e-03 | 8.42e-02 | 0.108 |
| 144165 | PRICKLE1 | P26T-E | Human | Esophagus | ESCC | 1.15e-06 | 3.16e-01 | 0.1276 |
| 144165 | PRICKLE1 | P30T-E | Human | Esophagus | ESCC | 1.06e-08 | 5.17e-01 | 0.137 |
| 144165 | PRICKLE1 | P31T-E | Human | Esophagus | ESCC | 3.82e-21 | 4.98e-01 | 0.1251 |
| 144165 | PRICKLE1 | P32T-E | Human | Esophagus | ESCC | 1.32e-08 | 2.44e-01 | 0.1666 |
| 144165 | PRICKLE1 | P37T-E | Human | Esophagus | ESCC | 1.61e-09 | 2.14e-01 | 0.1371 |
| 144165 | PRICKLE1 | P42T-E | Human | Esophagus | ESCC | 9.24e-10 | 3.94e-01 | 0.1175 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:0006913110 | Esophagus | ESCC | nucleocytoplasmic transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
| GO:0051169110 | Esophagus | ESCC | nuclear transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
| GO:0042176111 | Esophagus | ESCC | regulation of protein catabolic process | 280/8552 | 391/18723 | 8.65e-26 | 2.39e-23 | 280 |
| GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
| GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
| GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
| GO:1903320111 | Esophagus | ESCC | regulation of protein modification by small protein conjugation or removal | 181/8552 | 242/18723 | 1.80e-20 | 2.60e-18 | 181 |
| GO:1903362111 | Esophagus | ESCC | regulation of cellular protein catabolic process | 188/8552 | 255/18723 | 5.12e-20 | 6.62e-18 | 188 |
| GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
| GO:1903050111 | Esophagus | ESCC | regulation of proteolysis involved in cellular protein catabolic process | 163/8552 | 221/18723 | 1.44e-17 | 1.27e-15 | 163 |
| GO:0061136111 | Esophagus | ESCC | regulation of proteasomal protein catabolic process | 142/8552 | 187/18723 | 2.40e-17 | 2.00e-15 | 142 |
| GO:0045732111 | Esophagus | ESCC | positive regulation of protein catabolic process | 167/8552 | 231/18723 | 1.47e-16 | 1.14e-14 | 167 |
| GO:0031396111 | Esophagus | ESCC | regulation of protein ubiquitination | 154/8552 | 210/18723 | 2.70e-16 | 2.04e-14 | 154 |
| GO:0032434111 | Esophagus | ESCC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 107/8552 | 134/18723 | 4.06e-16 | 2.93e-14 | 107 |
| GO:2000058111 | Esophagus | ESCC | regulation of ubiquitin-dependent protein catabolic process | 125/8552 | 164/18723 | 1.17e-15 | 7.76e-14 | 125 |
| GO:001703818 | Esophagus | ESCC | protein import | 149/8552 | 206/18723 | 5.90e-15 | 3.31e-13 | 149 |
| GO:1903364111 | Esophagus | ESCC | positive regulation of cellular protein catabolic process | 117/8552 | 155/18723 | 3.25e-14 | 1.66e-12 | 117 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0431021 | Lung | AIS | Wnt signaling pathway | 39/961 | 171/8465 | 1.29e-05 | 3.32e-04 | 2.12e-04 | 39 |
| hsa0431031 | Lung | AIS | Wnt signaling pathway | 39/961 | 171/8465 | 1.29e-05 | 3.32e-04 | 2.12e-04 | 39 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PRICKLE1 | SNV | Missense_Mutation | rs376845777 | c.805G>A | p.Gly269Arg | p.G269R | Q96MT3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A08G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| PRICKLE1 | SNV | Missense_Mutation | c.2460N>C | p.Lys820Asn | p.K820N | Q96MT3 | protein_coding | deleterious(0) | benign(0.368) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PRICKLE1 | insertion | In_Frame_Ins | novel | c.1717_1718insTGATGGAAAATTCAACTTTTTTTGATTTTTTTT | p.Asp573delinsValMetGluAsnSerThrPhePheAspPhePheTyr | p.D573delinsVMENSTFFDFFY | Q96MT3 | protein_coding | TCGA-A2-A0ER-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| PRICKLE1 | insertion | Frame_Shift_Ins | novel | c.1748_1749insAC | p.Asn584ArgfsTer13 | p.N584Rfs*13 | Q96MT3 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PRICKLE1 | insertion | In_Frame_Ins | novel | c.1747_1748insGGACAACCAATCCCTCAACCCCGGCCACAGAGATTTGCC | p.Thr582_Leu583insTrpThrThrAsnProSerThrProAlaThrGluIleCys | p.T582_L583insWTTNPSTPATEIC | Q96MT3 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PRICKLE1 | SNV | Missense_Mutation | novel | c.1076N>G | p.Lys359Arg | p.K359R | Q96MT3 | protein_coding | tolerated(0.35) | benign(0.012) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PRICKLE1 | SNV | Missense_Mutation | novel | c.646N>A | p.Phe216Ile | p.F216I | Q96MT3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PRICKLE1 | SNV | Missense_Mutation | rs765119777 | c.434N>T | p.Ala145Val | p.A145V | Q96MT3 | protein_coding | deleterious(0.04) | possibly_damaging(0.894) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| PRICKLE1 | SNV | Missense_Mutation | c.2078N>A | p.Arg693Lys | p.R693K | Q96MT3 | protein_coding | tolerated(0.08) | benign(0) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PRICKLE1 | SNV | Missense_Mutation | novel | c.1936N>A | p.Glu646Lys | p.E646K | Q96MT3 | protein_coding | tolerated(0.76) | benign(0.001) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |